-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK now expects 20+ phase III trial starts in 2026, up from 10

PUBT·07/28/2026 11:18:34
Listen to the news
GSK now expects 20+ phase III trial starts in 2026, up from 10
  • GSK lifted its 2026 R&D outlook, now targeting more than 20 Phase III trial starts versus 10 previously.
  • The updated expectations follow Q2 2026 performance with total sales of £8.4 billion, up 5%, core operating profit of £2.8 billion, up 7%.
  • Management flagged a 3-year cost-savings program to fund late-stage portfolio investment, with some savings aimed at supporting margins in 2028-2030.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.